Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - prednisolone - oral tablet - 25mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - prednisolone - gastro-resistant tablet - 1mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - prednisolone - oral tablet - 1mg

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rifamycin sodium - capsule - 150mg, 300mg - active: rifamycin sodium

Арменија - Енглески - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

laboratoires bouchara-recordati 68 rue marjolin 92300 levallois perret - rifamycin (rifamycin sodium) - drops ear - 26mg (20000iu)/ml

Арменија - Енглески - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmaster - rifamycin (rifamycin sodium) - drops ear - 26mg (20000iu)/ml

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

norgine pharmaceuticals ltd - rifaximin - oral tablet - 550mg

Европска Унија - Енглески - EMA (European Medicines Agency)

pfizer ltd. - sitaxentan sodium - hypertension, pulmonary - antihypertensives, - treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.

Европска Унија - Енглески - EMA (European Medicines Agency)

schering-plough europe - posaconazole - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics for systemic use - posaconazole sp is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.posaconazole sp is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

Европска Унија - Енглески - EMA (European Medicines Agency)

gilead sciences international ltd - elvitegravir - hiv infections - antivirals for systemic use - vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human-immunodeficiency-virus-1 (hiv-1) infection in adults who are infected with hiv-1 without known mutations associated with resistance to elvitegravir.